Hot Growth Stocks To Buy For 2019

Analysts expect Crane Co. (NYSE:CR) to report sales of $842.46 million for the current quarter, Zacks Investment Research reports. Five analysts have issued estimates for Crane’s earnings, with the highest sales estimate coming in at $867.00 million and the lowest estimate coming in at $819.90 million. Crane reported sales of $702.50 million in the same quarter last year, which indicates a positive year over year growth rate of 19.9%. The firm is expected to issue its next earnings report on Monday, July 23rd.

According to Zacks, analysts expect that Crane will report full year sales of $3.38 billion for the current fiscal year, with estimates ranging from $3.35 billion to $3.43 billion. For the next year, analysts anticipate that the firm will report sales of $3.53 billion per share, with estimates ranging from $3.42 billion to $3.64 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side analysts that cover Crane.

Hot Growth Stocks To Buy For 2019: BioCryst Pharmaceuticals Inc.(BCRX)

Advisors’ Opinion:

  • [By Steve Symington]

    Shares of Idera Pharmaceuticals fell 20.4% after the biotech company announced the termination of its planned merger with BioCryst Pharmaceuticals (NASDAQ:BCRX).

  • [By Logan Wallace]

    BidaskClub upgraded shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) from a buy rating to a strong-buy rating in a research note issued to investors on Thursday morning.

  • [By Brian Feroldi]

    Shares ofIdera Pharmaceuticals (NASDAQ:IDRA), a clinical-stage biopharma focused on oncology and rare diseases, fell 16% as of 2:20 p.m. EDT on Wednesday after itsproposedmerger with BioCryst Pharmaceuticals (NASDAQ:BCRX) was called off. Shares of BioCryst were up about 1% on the news.

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on BioCryst Pharmaceuticals (BCRX)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Ethan Ryder]

    Get a free copy of the Zacks research report on BioCryst Pharmaceuticals (BCRX)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Hot Growth Stocks To Buy For 2019: Orexigen Therapeutics, Inc.(OREX)

Advisors’ Opinion:

  • [By Stephan Byrd]

    Media headlines about Orexigen Therapeutics (NASDAQ:OREX) have trended somewhat positive recently, Accern Sentiment Analysis reports. The research group rates the sentiment of media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Orexigen Therapeutics earned a coverage optimism score of 0.05 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 45.6752029162772 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

  • [By Paul Ausick]

    Orexigen Therapeutics Inc. (NASDAQ: OREX) traded down about 78% Monday and posted a new 52-week low of $0.31 after closing Friday at $1.40. The stock’s 52-week high is $4.46. Volume was around 7.5million, about 15 times the daily average. The company has filed for Chapter 11 bankruptcy.

  • [By Paul Ausick]

    Orexigen Therapeutics Inc. (NASDAQ: OREX) traded down about 12% Tuesday and posted a new 52-week low of $0.29 after closing Monday at $0.33. The stock’s 52-week high is $4.46. Volume was around 5.9 million, about 8 times the daily average. The company filed Monday for Chapter 11 bankruptcy.

Hot Growth Stocks To Buy For 2019: Biglari Holdings Inc.(BH)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of Biglari Holdings Inc. (NYSE: BH) were down 17 percent to $352.05. Washington Prime Group Inc. (NYSE: WPG) will replace Biglari Holdings in the S&P SmallCap 600 on Tuesday, May 1.

  • [By Logan Wallace]

    Biglari Holdings (NYSE:BH)’s share price reached a new 52-week high and low during trading on Monday . The company traded as low as $195.09 and last traded at $197.24, with a volume of 16566 shares. The stock had previously closed at $209.09.

  • [By Lisa Levin]

    Shares of Biglari Holdings Inc. (NYSE: BH) were down 20 percent to $339.00. Washington Prime Group Inc. (NYSE: WPG) will replace Biglari Holdings in the S&P SmallCap 600 on Tuesday, May 1.

  • [By Lisa Levin]

    Check out these big penny stock gainers and losers

    Losers
    World Fuel Services Corporation (NYSE: INT) tumbled 18 percent to $22.90 following Q1 results.
    Biglari Holdings Inc. (NYSE: BH) fell 17.4 percent to $349.52. Washington Prime Group will replace Biglari Holdings in the S&P SmallCap 600 on Tuesday, May 1.
    Flex Ltd. (NASDAQ: FLEX) dipped 15.7 percent to $14.03 after a mixed fourth quarter report.
    FormFactor, Inc. (NASDAQ: FORM) fell 15.3 percent to $11.65. FormFactor is expected to release Q1 results on May 2.
    Data I/O Corporation (NASDAQ: DAIO) dropped 14.3 percent to $6.24 following Q1 results.
    National Instruments Corporation (NASDAQ: NATI) fell 14.3 percent to $ 42.34 after reporting Q1 results.
    United States Steel Corporation (NYSE: X) dipped 14.2 percent to $32.37 following Q1 results.
    Civeo Corporation (NYSE: CVEO) dropped 13.5 percent to $3.33. Civeo posted a Q1 loss of $0.42 per share on sales of $101.504 million.
    athenahealth, Inc. (NASDAQ: ATHN) fell 12.4 percent to $125.310 after reporting Q1 results.
    Charter Communications, Inc. (NASDAQ: CHTR) shares tumbled 12.1 percent to $262.06 as the company posted Q1 results.
    Value Line, Inc. (NASDAQ: VALU) fell 11.3 percent to $19.10.
    Federated Investors, Inc. (NYSE: FII) shares dropped 11.2 percent to $27.605 after the company posted downbeat quarterly earnings.
    AV Homes, Inc. (NASDAQ: AVHI) declined 10.7 percent to $17.20 following Q1 results.
    CalAmp Corp. (NASDAQ: CAMP) dropped 9.4 percent to $21.01 after reporting Q4 results.
    Tandem Diabetes Care, Inc. (NASDAQ: TNDM) shares fell 8.9 percent to $7.280 following mixed Q1 results.
    Sony Corporation (NYSE: SNE) shares fell 8.4 percent to $45.97 after reporting Q4 results.
    LogMeIn Inc (NASDAQ: LOGM) fell 8.2 percent to $109.825. LogMeIn reported upbeat earnings for its first quarter, but issued weak second quarter and FY18 earning guidance.
    Eleven Biotherapeutics, Inc. (NASDAQ: EBIO

Leave a Reply

Your email address will not be published. Required fields are marked *